An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

NCT04343768 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Hydroxychloroquine
DRUG: Lopinavir / Ritonavir
DRUG: Interferon Beta-1A
DRUG: Interferon Beta-1B

Sponsor

Shahid Beheshti University of Medical Sciences